The Key Technologies in Industrialization of Pediatric Preparations
JIANG Dong, SONG Hui, JIN Wen-zhen, ZHENG Wen-sheng*
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Beijing 100050, China
Abstract：The children aged 0-14 account for about 17% of the total population of China, medicines used by which cost more than 60 billion yuan per year. However, it is difficult for children to swallow medicines and children are more sensitive to taste. In addition, the gastrointestinal, liver and kidney functions are not yet fully developed and the immune function is weak. There are special needs for active pharmaceutical ingredient, dosage form, taste and appearance. However, there is a significant gap between China and Europe and America on pediatric preparations. To promote the breakthrough of key as taste-masking technologies, solubilizing technologies, quantitative dosing devices, technologies in industrialization of pediatric preparations in China, the key technologies, such pediatric excipients and production equipment, are reviewed.
Tabulation on the 2000 population census of the People′s Republic of China Vol ⅡI(中国2010年人口普查资料,第三卷) (K). 2010. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.html.
[2]
Children′s Hospital of Chongqing Medical University. Rational Medication for Pediatric Diseases(临床药物治疗学:儿科疾病)[M]. Chapter 1. Beijing: People′s Medical Publishing House, 2011:1.
[3]
LI Y J, YANG S M. Analysis and evaluation of medicines of children′s in national essential medicine list[J]. Chin Pharm Aff (中国药事), 2014, 28(4):349-351.
[4]
SOHI H, SULTANA Y, KHAR R K. Taste masking technologies in oral pharmaceuticals: recent developments and approaches[J]. Drug Develop Ind Pharm, 2004, 30(5):429-448.
[5]
LEGIN A, RUDNITSKAYA A, CLAPHAM D, et al. Electronic tongue for pharmaceutical analytics: quantification of tastes and masking effects[J]. Anal Bioanal Chem, 2004, 380(1):36-45.
[6]
LI X L, QIU J X, LIU R X, et al. Changes of fingerprints of radix gentianae before and after taste masking[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2013, 19(17):104-106.
[7]
REN S L, WANG Y J, ZHENG Y, et al. Taste masking and evaluation based on the mechanism of bitterness[J]. Cent South Pharm (中南药学), 2014, 12(6):562-566.
[8]
DONYA A, HETTIARACHCHY N S, LIYANAGE R, et al. Effects of processing methods on the proximate composition and momordicosides K and L content of bitter melon vegetable[J]. J Agric Food Chem, 2007, 55(14):5827-5833.
[9]
CHUNG H S, LEE S Y. Modification of ginseng flavors by bitter compounds found in chocolate and coffee[J]. J Food Sci, 2012, 77(6):202-210.
[10]
ZHAO H Y. Study on masking technology of coptis chinensis extract[J]. Heilongjiang Med J (黑龙江医药), 2016, 29(4):605-607.
[11]
KAYUMBA P C, TWAGIRUMUKIZA M, HUYGHEBAERT N, et al. Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated plasmodium falciparum malaria[J]. Ann Tropic Paediatr, 2008, 28(2):103-109.
[12]
WALSH J, CRAM A, WOERTZ K, et al. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients[J]. Adv Drug Deliv Rev, 2014, 73: 14-33.
[13]
PATIL H, FENG X, MAJUMDAR S, et al. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach[J]. Am Assoc Pharm Sci J, 2014, 17(1):194-205.
[14]
RAYMOND Y, CHAMPAGNE C P. Dissolution of lipid-based matrices in simulated gastrointestinal solutions to evaluate their potential for the encapsulation of bioactive ingredients for foods[J]. Int J Food Sci, 2014:Article ID 749630.
[15]
HUANG S, MAO C, WILLIAMS R O 3rd, et al. Solubility advantage (and disadvantage) of pharmaceutical amorphous solid dispersions[J]. J Pharm Sci, 2016, 105(12):3549-3561.
[16]
BOHIN M C, ROLAND W S, GRUPPEN H, et al. Evaluation of the bitter-masking potential of food proteins for EGCG by a cell-based human btter taste receptor assay and binding studies[J]. J Agric Food Chem, 2013, 61(42):10010-10017.
[17]
WILDE S C, KEPPLER J K, PALANI K, et al. β-Lactoglobulin as nanotransporter for allicin: sensory properties and applicability in food[J]. Food Chem, 2016, 199: 667-674.
[18]
SHAH P P, MASHRU R C. Palatable reconstitutable dry suspension of artemether for flexible pediatric dosing using cyclodextrin inclusion complexation[J]. Pharm Develop Technol, 2010, 15(3):276-285.
[19]
BREWSTER M E, LOFTSSON T. Cyclodextrins as pharmaceutical solubilizers[J]. Adv Drug Deliv Rev, 2007, 59(7):645-666.
[20]
XIANG Z Y, LI X F, ZHU N, et al. Preparation of the resin complexes masking bitterness of gentianae radix total glycosides extract[J]. Chin Tradit Pat Med (中成药), 2016, 38(4):785-790.
[21]
WOERTZ K, TISSEN C, KLEINEBUDDE P, et al. Rational development of taste masked oral liquids guided by an electronic tongue[J]. Int J Pharm, 2010, 400(1-2):114-123.
[22]
KULKARNI M G, MENJOGE A R. pH Sensitive polymer and process for preparation thereof: United States, 7531612[P]. 20090512.
[23]
ALAYOUBI A, DAIHOM B, ADHIKARI H, et al. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin amberlite IRP 69 for use in pediatrics[J]. Drug Develop Ind Pharm, 2016, 42(10):1579-1589.
[24]
MARTIN DEL CALLE E M. Cyclodextrins and their uses: a review[J]. Proc Biochem, 2004, 39(9):1033-1046.
[25]
MULLER R H, PETERS K, BECKER R, et al. Nanosuspension for the i.v. administration of poorly soluble drugs—stability during sterilization and long-term storage[C]. Proceedings of the 22nd International Symposium on Controlled Release of Bioactive Materials, Seattle, Controlled Release Society, 1995:574-575.
[26]
PINNAMANENI S, DSA N G, DSA S K. Formulation approaches for orally administered poorly soluble drugs[J]. Pharmazie, 2002, 57(5):291-300.
[27]
LIVERSIDGE G G, CUNDY K C, BISHOP J, et al. Surface modified drug nanoparticles: United States, 5145684[P]. 19920614.
[28]
MULLER R H, BECKER R, KRUSS B, et al. Pharmaceutical nanosuspensions for medical administration as system of increased saturation solubility and rate of solution: United States, 5858410[P]. 19950523.
[29]
TIWARY A K. Modification of crystal habit and its role in dosage form performance[J]. Drug Develop Ind Pharm, 2001, 27(7):600-709.
[30]
MAGHSOODI M. Role of solvents in improvement of dissolution rate of drugs: crystal habit and crystal agglomeration[J]. Adv Pharm Bull, 2015, 5(1):13-18.
[31]
MARRARO G A. Perspectives for use of surfactant in children and adult[J]. J Mater-Fetal & Neonat Med, 2004, 16(2):29-31.
[32]
FABIANO V, MAMELI C, ZUCCOTTI G V. Paediatric pharmacology: remember the excipients[J]. Pharm Res, 2011, 63(5):362-365.
[33]
SALUNKE S, BRANDYS B, GIACOIA G, et al. The STEP (safety and toxicity of excipients for paediatrics) database: part 2-the pilot version[J]. Int J Pharm, 2013, 457(1):310-322.
[34]
SCADDING G. Pediatric allergy medications: review of currently available formulations[J]. Curr Med Res Opin, 2009, 25(5):2069-2079.
[35]
STRICKLEY R G, IWATA Q, WU S, et al. pediatric drugs-a review of commercially available oral formulations[J]. J Pharm Sci, 2008, 97(5):1731-1774.
[36]
SUN G N, REN Q, LI J, et al. New measures in preparation of orally disintegrating tablets[J]. Chin J Pharm (中国医药工业杂志), 2008, 39(11):866-869.
[37]
LU Y, JIN Y B, WANG S M, et al. Property evaluation of co-processed excipient of mannitol and polyplasdone and its application in orally disintegrating tablets[J]. Chin Pharm J (中国药学杂志), 2016, 51(9):715-722.
[38]
LI F, LI B L, WANG J Z, et al. Preparation and quality control of famotidine effervescent tablets[J]. Chin J Mod Appl Pharm (中国现代应用药学), 2011, 28(4):335-337.
[39]
LIANG A M, LIN H Q. Clarithromycin dry suspension and its preparation method: China, 200410027712.9[P]. 20050316.
[40]
ZAJICEK A, FOSSLER M J, BARRETT J S, et al. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms[J]. Am Assoc Pharm Sci J, 2013, 15(4):1072-1081.
[41]
PERUMAL O, MURTHY S N, KALIA Y N. Turning theory into practice: the development of modern transdermal drug delivery systems and future trends[J]. Skin Pharmacol Physiol, 2013, 26(4-6):331-342.
[42]
GOLDSTEIN J, SMITH T R, PUGACH N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine[J]. Headache, 2012, 52(9):1402-1410.
[43]
VINCKEN W, DEKHUIJZEN R, BARNES P, et al. The ADMIT series-Issues in Inhalation Therapy. 4) How to choose inhaler devices for the treatment of COPD[J]. Primary Care Respir J, 2010, 19(1):10-20.
2019, Vol. 54 
